Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
MWN-AI** Summary
Windtree Therapeutics, Inc. has announced a significant transaction involving the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC (SPH), a private investment group based in North Carolina. Under the terms of the agreement, Windtree will receive 20% of any future milestone and royalty payments associated with the commercial success of the acquired drug candidates, which target acute heart failure (AHF). The AHF market is substantial, with millions of hospital admissions in the US and EU, translating into a potential global market value in the billions.
Notably, Windtree stands to receive a contingent payment of $700,000 from SPH, which will be triggered if SPH completes a financing round generating at least $10 million in gross cash proceeds. This financing is aimed at supporting the development of the cardiovascular assets acquired from Windtree. Additionally, Windtree will transfer certain development payables related to the cardiovascular drug candidates to SPH, alleviating Windtree of further obligations to fund their development.
Jed Latkin, CEO of Windtree, expressed satisfaction with the agreement, highlighting the benefits of obtaining a non-dilutive cash inflow while maintaining rights to future proceeds. The partnership not only secures potential future financial benefits for Windtree but also fulfills the pressing need for innovative AHF therapies.
As Windtree continues its focus on generating revenue and achieving future profitability, this deal represents a strategic move to streamline operations while capitalizing on the promising aspects of its cardiovascular drug portfolio. For further details about Windtree and its initiatives, visit their official website.
MWN-AI** Analysis
The recent announcement by Windtree Therapeutics, Inc. regarding the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC, marks a pivotal shift that investors should closely monitor. Windtree will receive 20% of any future economic benefits from these assets, including global commercial net revenues if approved for acute heart failure (AHF) treatment. The global AHF market's potential, exceeding billions of dollars given the substantial hospital admissions in the U.S. and EU, presents a significant revenue opportunity for Windtree.
Investors should appreciate the strategic nature of this transaction. By transferring the burden of development payables, Windtree alleviates financial strain while positioning itself to benefit from success down the line. The immediate $700,000 payment, contingent upon a $10 million financing round, injects much-needed liquidity without diluting existing shareholder equity.
Moreover, Windtree's strategy underscores its goal of becoming a revenue-generating entity. With a growing focus on monetizing its portfolio effectively, the company is drawing investment interest while safeguarding against financial pitfalls inherent in drug development.
However, potential investors must also remain cognizant of the inherent risks associated with such arrangements. The future success of these drug candidates hinges on regulatory approvals and market acceptance, both of which carry uncertainties that could impact projected revenues.
In summary, Windtree Therapeutics appears to be on a prudent path to unlocking value for its shareholders through strategic partnerships. The sale provides a dual benefit: immediate financial relief and a potential revenue stream from future milestones. Investors should consider monitoring developments closely, particularly the outcome of Seismic Pharmaceutical's financing efforts and subsequent regulatory progress. With the right market conditions, Windtree could emerge as a more robust player in the biotech sector, making it a potentially attractive investment in a lucrative niche.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues)
Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000
Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings
WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a revenue generating company, announced that it has signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical Holdings, LLC. (“SPH”), a private investment group based in North Carolina, USA.
Windtree is entitled to 20% of any future proceeds received by SPH. This would include global commercial net revenue in acute heart failure (AHF) if approved by regulatory authorities. There were 2.1 and 2.7 million AHF hospital admissions in 2022 in the US and EU respectively. Windtree believes that the AHF global drug market value is in the billions of dollars. If the buyer conducts a financing of at least $10MM to fund development of the assets, Windtree would receive a payment of $700k from the proceeds. Additionally, as part of the agreement, Windtree will transfer certain cardiovascular drug candidate development payables to SPH.
“We are pleased to have the rights for 20% of future proceeds for the cardiovascular drug candidates, non-dilutive cash contingent on a future financing of at least $10MM and the transfer of substantial development payables to the buyer,” said Jed Latkin, Chief Executive Officer of Windtree. “We are proud of the work Windtree has done to develop the drug candidates and to enter into an agreement where there is no more obligation for our Company to fund development while receiving rights to potentially significant future payments from proceeds. Additionally, Patients and providers need AHF drug innovation and we believe these drug candidates represent innovation.”
For more information, see our public filings at www.windtreetx.com.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions and focused on becoming a revenue generating company with future profitability.
About Seismic Pharmaceutical Holdings, LLC
Seismic Pharmaceutical Holdings, LLC, is a private investment group based in North Carolina, USA.
Forward Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: risks related to the Company’s ability to begin its environmental services business and manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ**
How does Windtree Therapeutics Inc. (WINT) plan to utilize its 20% share of future proceeds from Seismic Pharmaceutical Holdings, LLC for their cardiovascular drug candidates?
What are the specific terms of the financing round that will trigger the $700,000 payment to Windtree Therapeutics Inc. (WINT) from Seismic Pharmaceutical Holdings, LLC?
Can Windtree Therapeutics Inc. (WINT) provide more details on the cardiovascular development payables being transferred to Seismic Pharmaceutical Holdings, LLC and their impact on its financial position?
What is Windtree Therapeutics Inc. (WINT)'s strategy for leveraging potential commercial net revenues from the acute heart failure market, given the projected billions in market value?
**MWN-AI FAQ is based on asking OpenAI questions about Windtree Therapeutics Inc. (NASDAQ: WINT).
NASDAQ: WINT
WINT Trading
-12.12% G/L:
$0.116 Last:
1,921,610 Volume:
$0.132 Open:
